DSIP vs Semax: What Was Studied?
DSIP has small, conflicting human insomnia studies. Semax has human studies in ischemic-stroke care and rehabilitation, plus separate animal mechanism work. Those different settings do not support a head-to-head effectiveness ranking or a claim that the peptides work safely together.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
DSIP
Dossier overview
Semax
Dossier overview
Different populations and outcomes
DSIP (emideltide) was tested intravenously in small human insomnia studies. Early reports described improved sleep measures in some participants (PMID 7028502; PMID 3622582). A later crossover study found little clinical significance, and a 16-person placebo-controlled study concluded that short-term DSIP was unlikely to provide a major therapeutic benefit (PMID 3583493; PMID 1299794). FDA’s 2026 review found the intravenous evidence inconclusive and no effectiveness study for the proposed subcutaneous route (FDA emideltide briefing, pp. 24–31). The evidence for human insomnia benefit is very low.
Semax was examined in different clinical settings. A 1997 Russian-language report compared 30 people given Semax during acute ischemic-stroke care with 80 receiving conventional care and reported differences in neurological recovery measures; the abstract does not establish a modern randomized efficacy estimate (PMID 11517472). A 2018 report followed 110 people during stroke rehabilitation in groups with or without Semax and measured plasma BDNF, motor function, and Barthel index; its group and rehabilitation context matter when interpreting the reported associations (PMID 29798983). A separate rat study measured hippocampal BDNF/trkB expression after Semax, which is not human evidence of improved memory or sleep (PMID 16996037).
| Reader question | DSIP evidence | Semax evidence |
|---|---|---|
| Insomnia | Small, conflicting human intravenous studies | The cited stroke studies did not test insomnia |
| Stroke outcomes | The cited DSIP insomnia studies did not test stroke care | Small clinical reports in acute stroke and rehabilitation, with design limits |
| Direct comparison or combination | Not tested in the cited papers | Not tested in the cited papers |
Limits and safety context
The cited papers provide no DSIP-versus-Semax trial and no evidence that their combination is safe or beneficial. A hormone-marker study of DSIP in 11 healthy men found lower ACTH-like immunoreactivity but no change in plasma or urinary cortisol, so “DSIP reduces cortisol” is inaccurate (PMID 2554357). FDA’s 2026 emideltide briefing proposed against including its free-base and acetate forms on the 503A bulks list; that proposal is not a final approval decision (FDA briefing, pp. 52–55). This page makes no current-country approval claim for Semax without a verified primary regulatory record.
This page is for research education. It is not treatment, dosing, combination, or purchasing guidance.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.